|

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

RECRUITINGPhase 2Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 2
SponsorEli Lilly and Company
Started2026-08-27
Est. completion2027-05
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations30 sites

Summary

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* hsCRP ≥2 mg/L and ≤15 mg/L at screening
* At least one of the following chronic conditions:

  * Established atherosclerotic cardiovascular disease (ASCVD)
  * Obesity (body mass index (BMI) ≥30 kg/m2)
  * Type 2 diabetes
  * Hypertension
  * Chronic kidney disease Grade 3 or 4

Exclusion Criteria:

* Acute cardiovascular event within 60 days prior to screening
* Acute decompensated heart failure hospitalization within 60 days prior to screening
* Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
* New York Heart Association Class III or IV heart failure
* Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
* Type 1 diabetes
* Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
* Nephrotic syndrome, estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², or history of kidney transplant
* Dialysis or acute kidney injury within 60 days prior to screening
* Congenital/hereditary kidney disease, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis
* Active tuberculosis, untreated latent tuberculosis, or known hepatitis B or hepatitis C infection
* Serious, opportunistic, chronic, or recurrent infection requiring treatment within 12 weeks prior to screening
* Significant active autoimmune disease
* Suspected or confirmed immunocompromised state (e.g., HIV infection)
* History of peptic ulcer disease or gastrointestinal ulceration within 12 months prior to screening
* History of symptomatic diverticular disease (diverticulitis), gastrointestinal perforation, or major gastrointestinal surgery
* Mechanical heart valve prosthesis requiring chronic vitamin K antagonist anticoagulation
* Use of colchicine within 14 days prior to screening or anticipated need during the study
* Use of immunosuppressive or immunomodulatory agents, including other biologic anti-IL-6 therapies, within specified windows prior to screening
* Use of systemic corticosteroids within 14 days prior to screening
* Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs)

Conditions7

AtherosclerosisCardiovascular DiseaseDiabetesDiabetes Mellitus, Type 2HypertensionObesityRenal Insufficiency, Chronic

Interventions1

Locations30 sites

Heart Center Research, LLC
Huntsville, Alabama, 35801
256-519-8472
Pima Heart
Tucson, Arizona, 85741
717-615-0659
Eclipse Clinical Research
Tucson, Arizona, 85745
520-647-9926
Thrive Clinical Research Group
Glendora, California, 91740
626-727-7254
Omega Research Orlando
Altamonte Springs, Florida, 32714
386-668-4202

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.